Integer (ITGR) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Integer (ITGR) has outperformed Stereotaxis (STXS) over the past year, gaining 22.0% versus a loss of 64.5%. Over five years, ITGR leads with a +41.8% price change compared with -80.9% for STXS. Integer is the larger company by market cap ($4.31 billion vs $113.2 million), about 38.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ITGR | STXS |
|---|---|---|
| Share price | $126.65 | $1.13 |
| Market cap | $4.31B | $113.23M |
| 1-day change | +0.05% | 0.00% |
| YTD return | +61.41% | -50.87% |
| 1-year return | +22.05% | -64.47% |
| 5-year return | +41.79% | -80.94% |
| P/E ratio (TTM) | 34.60 | — |
| Forward P/E | 18.44 | — |
| EPS (TTM) | $3.66 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.85B | — |
| Revenue growth (YoY) | +7.98% | — |
| Net income (latest FY) | $102.81M | — |
| Gross margin | 26.99% | — |
| Operating margin | 11.94% | — |
| Net margin | 5.55% | — |
| 52-week high | $126.80 | $3.59 |
| 52-week low | $62.00 | $1.09 |
| Distance from 52-week high | -0.12% | -68.52% |
| Analyst consensus | none | — |
| Avg. price target upside | -3.83% | — |
| Average volume | 981.56K | 809.88K |
| Shares outstanding | 34.00M | 100.20M |
| Employees | 11,000 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Integer is about 38.0 times larger than Stereotaxis by market value ($4.31B vs $113.23M).
- ITGR has outperformed STXS by 86.5 percentage points over the past year.
About Integer
ITGR stock →Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 11,000 employees
ITGR vs STXS FAQ
Which is bigger, Integer or Stereotaxis?
Integer (ITGR) is larger, with a market capitalization of $4.31B compared with $113.23M for Stereotaxis (STXS).
Which stock has performed better over the past year, ITGR or STXS?
ITGR returned +22.05% over the past 12 months, compared with -64.47% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Integer and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.